The market for drugs to treat chronic pain is large and growing rapidly.

The market for drugs to treat chronic pain is large and growing rapidly.

About Relmada

Relmada Therapeutics, Inc. is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain.  Learn More 
 

 

Our Product Candidates

LevoCap ER is a proprietary once-a-day extended release dosage form of the opioid analgesic levorphanol in an abuse deterrent drug delivery system. It has activity at both opioid and non-opioid receptors. Unlike oxycodone, morphine, hydromorphone, oxymorphone, and hydrocodone, levorphanol modulates pain through both the ascending opioidergic pathways and the descending noradrenergic pathways in one centrally acting analgesic. Learn More
 
d-Methadone is the d optical isomer of racemic methadone and an antagonist at the N-methyl-D-aspartate (NMDA) receptor. NMDA antagonists have also been shown to reduce tolerance and  to opioid analgesics in experimental models. Racemic (d + l-methadone) methadone has been available in the United States for over 60 years. Learn More
 
MepiGel is a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia and painful HIV-associated neuropathy. Learn More
 
BuTab ER is a proprietary once-a-day extended release dosage form of oral buprenorphine. It is being developed for the treatment of chronic moderate to moderately severe pain and opioid dependence. Buprenorphine has been widely used by the sublingual and transdermal, but not by the oral route. Learn More